This finding is often interpreted as ‘non-informative’ because the residual cancer risk is high which represents a difficult challenge in the clinic given that there is no consensus on whether high-risk women who are BRCA mutation-negative should follow the same preventive measures as women with an identified BRCA1/2 mutation. The gene discussed is BRCA1; the disease is cancer.